Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6458926 | 0.80 | — | — | |
| SCHEMBL6813007 | 0.76 | — | — | |
| SCHEMBL646063 | 0.75 | GAA (0.36) | GAAMEN1KMT2A | |
| SCHEMBL2019127 | 0.72 | GAA (0.35) | GAAMEN1KMT2A | |
| SCHEMBL6815106 | 0.71 | — | — | |
| SCHEMBL6815100 | 0.71 | — | — | |
| SCHEMBL13009231 | 0.71 | GAA (0.33) | GAAMEN1KMT2A | |
| SCHEMBL13460338 | 0.70 | — | — | |
| SCHEMBL7472204 | 0.69 | TSHR (0.60) | GAAMEN1KMT2A | |
| SCHEMBL7478396 | 0.68 | NAAA (0.44) | GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2993168-B1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | BASF SE (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2993168-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | BASF SE (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-1807395-B1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | BASF SE (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20150031879-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | BASF SE (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031879-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | BASF SE (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20130041148-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | BASF SE (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130041148-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | BASF SE (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20110015315-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | FREY MARKUS | 2011-01-20 | — | — | US | disclosed |
| US-20110015315-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | FREY MARKUS | 2011-01-20 | — | — | US | disclosed |
| US-20090069470-A1 | Process for the synthesis of n-alkoxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2009-03-12 | — | — | US | disclosed |
| US-20090069470-A1 | Process for the synthesis of n-alkoxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2009-03-12 | — | — | US | disclosed |
| EP-1121347-B1 | PROCESS FOR THE SYNTHESIS OF 4-SUBSTITUTED N- (ALK-2- EN-1-YL)OXY]- AND N-ARALKYLOXY- 2,2,6,6- TETRAALKYLPIPERIDINES | CIBA SC HOLDING AG (CH) | 2004-07-07 | — | — | EP | disclosed |
| EP-1121347-A1 | PROCESS FOR THE SYNTHESIS OF 4-SUBSTITUTED N- (ALK-2- EN-1-YL)OXY]- AND N-ARALKYLOXY- 2,2,6,6- TETRAALKYLPIPERIDINES | Ciba Spezialitätenchemie Holding AG (Ciba Spécialités Chimiques Holding SA) (Ciba Specialty Chemicals Holding Inc.) (CH) | 2001-08-08 | — | — | EP | disclosed |
| US-6211378-B1 | OXIDATION OF N-H COMPOUND TO FORM N-OXYL DERIVATIVE, REACTING TWO EQUIVALENTS OF N-OXYL COMPOUND WITH ONE EQUIVALENT OF A COMPOUND HAVING AN ALLYLIC HYDROGEN, A BENZYLIC HYDROGEN OR AN ACTIVATED METHINE HYDROGEN TO FORM N-OH AND N-OR COMPOUNDS | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-04-03 | — | — | US | disclosed |
| WO-2000021933-A1 | PROCESS FOR THE SYNTHESIS OF 4-SUBSTITUTED N-[(ALK-2- EN-1-YL)OXY]- AND N-ARALKYLOXY- 2,2,6,6- TETRAALKYLPIPERIDINES | CIBA SPECIALITY CHEMICALS HOLDING INC. (CH) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069470-A1 | Process for the synthesis of n-alkoxyamines | PNMT, PAOX, PAH | GAA 2206/4885MEN1 4716/4885KMT2A 1092/4885 |
| US-20110015315-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | PNMT, PAH, PAOX | GAA 2370/4885MEN1 4566/4885KMT2A 1090/4885 |
| US-20150031879-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | PNMT, PAH, PAOX | GAA 2370/4885MEN1 4566/4885KMT2A 1090/4885 |
| US-20130041148-A1 | PROCESS FOR THE SYNTHESIS OF N-ALKOXYAMINES | PNMT, PAH, PAOX | GAA 2370/4885MEN1 4566/4885KMT2A 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.